BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 34372813)

  • 1. Bone responsiveness to parathyroid hormone is negatively associated with parathyroid hormone-lowering drug use in patients undergoing hemodialysis: a cross-sectional study.
    Tominaga N; Yonaha T; Yamanouchi M; Sumi H; Taki Y; Shibagaki Y; Shiizaki K; Yano S
    BMC Nephrol; 2021 Aug; 22(1):275. PubMed ID: 34372813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the Intravenous Calcimimetic Etelcalcetide on Bone Turnover and Serum Fibroblast Growth Factor 23: Post Hoc Analysis of an Open-label Study.
    Shigematsu T; Fukagawa M; Yokoyama K; Akiba T; Fujii A; Odani M; Akizawa T
    Clin Ther; 2018 Dec; 40(12):2099-2111. PubMed ID: 30473399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased undercarboxylated osteocalcin/intact osteocalcin ratio in patients undergoing hemodialysis.
    Nagata Y; Inaba M; Imanishi Y; Okazaki H; Yamada S; Mori K; Shoji S; Koyama H; Okuno S
    Osteoporos Int; 2015 Mar; 26(3):1053-61. PubMed ID: 25403902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Lowering Dialysate Calcium Concentration on Bone Metabolic Markers in Hemodialysis Patients With Suppressed Serum Parathyroid Hormone: A Preliminary Study.
    Niwa H; Fukasawa H; Ishibuchi K; Kaneko M; Yasuda H; Furuya R
    Ther Apher Dial; 2018 Oct; 22(5):503-508. PubMed ID: 29923680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower Bone Turnover and Skeletal PTH Responsiveness in Japanese Compared to European Patients on Hemodialysis.
    Evenepoel P; Jørgensen HS; Komaba H; Mazzaferro S; Vervloet M; Cavalier E; Fukagawa M
    J Clin Endocrinol Metab; 2022 Nov; 107(12):e4350-e4359. PubMed ID: 36068939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
    Avbersek-Luznik I; Balon BP; Rus I; Marc J
    Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tartrate-resistant acid phosphatase--TRAP 5b--as a novel marker of bone resorption in patients with irreversible renal failure treated with dialysis].
    Nowak Z; Konieczna M; Wańkowicz Z
    Pol Merkur Lekarski; 2004 Aug; 17(98):138-41. PubMed ID: 15603322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of parathyroidectomy on blood bone markers and heart rate variability in patients with stage 5 chronic kidney disease.
    Chen H; Cui Y; Xing C; Purrunsing Y; Zha X; Shen C; Zeng M; Yang G; Yu X; Zhang L; Jiang Y; Shen Z; Ma H; Yin C; Li Y; Wang N
    Int Urol Nephrol; 2018 Dec; 50(12):2279-2288. PubMed ID: 30361964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum magnesium concentration is an independent predictor of parathyroid hormone levels in peritoneal dialysis patients.
    Navarro JF; Mora C; Macia M; Garcia J
    Perit Dial Int; 1999; 19(5):455-61. PubMed ID: 11379859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between biochemical markers and radial cortical bone changes in hemodialysis patients.
    Fujimori A; Okada S; Sakai M; Tome K; Fukagawa M
    Nephron Clin Pract; 2011; 118(4):c375-9. PubMed ID: 21325869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of vitamin K2 in hemodialysis patients with low serum parathyroid hormone levels.
    Nakashima A; Yorioka N; Doi S; Masaki T; Ito T; Harada S
    Bone; 2004 Mar; 34(3):579-83. PubMed ID: 15003806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significant inverse relationship between serum undercarboxylated osteocalcin and glycemic control in maintenance hemodialysis patients.
    Okuno S; Ishimura E; Tsuboniwa N; Norimine K; Yamakawa K; Yamakawa T; Shoji S; Mori K; Nishizawa Y; Inaba M
    Osteoporos Int; 2013 Feb; 24(2):605-12. PubMed ID: 22581293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Effect of Calcimimetics on Osteoclast-Osteoblast Crosslink in Chronic Kidney Disease and Mineral Bone Disease.
    Hung KC; Chang JF; Hsu YH; Hsieh CY; Wu MS; Wu MY; Chiu IJ; Syu RS; Wang TM; Wu CC; Hung LY; Zheng CM; Lu KC
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33218086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis.
    Chu P; Chao TY; Lin YF; Janckila AJ; Yam LT
    Am J Kidney Dis; 2003 May; 41(5):1052-9. PubMed ID: 12722040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of raloxifene on bone metabolism in postmenopausal women on chronic hemodialysis.
    Nagatoya K; Nishimoto K; Shibahara N; Takahashi T; Kanehara H; Ueno N; Yasuda H; Okada S; Ueda H; Hirai K; Inoue T;
    Clin Exp Nephrol; 2015 Oct; 19(5):939-46. PubMed ID: 25504368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis.
    Yamada S; Tsuruya K; Yoshida H; Taniguchi M; Haruyama N; Tanaka S; Eriguchi M; Nakano T; Kitazono T
    Clin Endocrinol (Oxf); 2013 Jun; 78(6):844-51. PubMed ID: 23078546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO Survey.
    Cozzolino M; Brancaccio D; Cannella G; Messa P; Gesualdo L; Marangella M; LoDeserto C; Pozzato M; Rombolà G; Costanzo AM; di Luzio Paparatti U; Mazzaferro S;
    Nephrol Dial Transplant; 2012 Sep; 27(9):3588-94. PubMed ID: 22523119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between intact PTH and biointact PTH (1-84) with bone and mineral metabolism in pre-dialysis chronic kidney disease (CKD).
    O'Flaherty D; Sankaralingam A; Scully P; Manghat P; Goldsmith D; Hampson G
    Clin Biochem; 2013 Oct; 46(15):1405-9. PubMed ID: 23830844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D receptor gene polymorphism detected by digestion with Apa I influences the parathyroid response to extracellular calcium in Japanese chronic dialysis patients.
    Yokoyama K; Shigematsu T; Kagami S; Tsukada T; Arai T; Hara S; Yamada A; Kawaguchi Y; Hosoya T
    Nephron; 2001 Nov; 89(3):315-20. PubMed ID: 11598396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.